B · Normal
[It was announced before it was announced that the subcutaneous PD-L1 antibody drug envolimab had received routine approval] On November 20, it was announced before it was announced that it had entered into a partnership with Alphamab Alpha Biopharmaceuticals and Silidi Pharmaceuticals. (1244.HK)’s collaborative subcutaneous PD-L1 antibody drug Envida® (envolimab injection) is used for the indication of microsatellite high instability (MSI-H)/mismatch repair gene deficient (dMMR) adult advanced solid tumors. It has been reviewed and approved by the National Medical Products Administration and has been converted from conditional approval to routine approval. At the same time, the new 600 mg once every three weeks (Q3W) dosage regimen has also been approved.
medicine 🕐 2026-11-20 11:03

Related telegraphs

Comments

0/500
Captcha (click to refresh)
No comments yet